A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men with Metastatic Castrate Resistant Prostate Cancer

Trial Profile

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men with Metastatic Castrate Resistant Prostate Cancer

Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Tasquinimod (Primary)
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Active Biotech
  • Most Recent Events

    • 06 Jun 2017 Results highlighting the use of an automated bone scan index (aBSI) in men with bone-metastatic castration-resistant prostate cancer (CRPC) from this trial, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 02 Jun 2017 Results highlighting the use of an automated bone scan index (aBSI) in men with bone-metastatic castration-resistant prostate cancer (CRPC) from this trial will be presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, according to a Progenics Pharmaceuticals media release.
    • 13 Jun 2016 Results published in the Journal of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top